Supplemental Digital Content 6. Unadjusted and adjusted association between core agent and type 2 diabetes mellitus using pooled logistic regression with and without inverse probability of censoring weights and time-updated covariates

	# T2DM events	Unadjusted OR (95% CI)	Unadjusted, IPCW OR (95% CI)	Adjusted[a] OR (95% CI)	Adjusted[a], IPCW OR (95% CI)
ART-naïve PLHIV					
DTG	44	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
EVG/c	39	0.66 (0.44, 0.99)	0.67 (0.45, 1.01)	0.73 (0.49, 1.10)	0.76 (0.49, 1.12)
bDRV	10	0.71 (0.36, 1.39)	0.72 (0.37, 1.42)	0.52 (0.26, 1.05)	0.54 (0.27, 1.07)
ART-experienced/suppressed PLHIV					
DTG	80	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
EVG/c	67	0.76 (0.55, 1.05)	0.75 (0.54, 1.04)	0.96 (0.69, 1.33)	0.95 (0.68, 1.32)
RAL	14	1.07 (0.60, 1.90)	1.07 (0.61, 1.91)	0.94 (0.52, 1.69)	0.94 (0.53, 1.70)
bDRV	24	1.02 (0.64, 1.61)	1.03 (0.65, 1.63)	0.96 (0.60, 1.53)	0.97 (0.61, 1.54)

ART, antiretroviral therapy; bDRV, boosted darunavir; CI, confidence interval; DTG, dolutegravir; EVG/c, elvitegravir with cobicistat; IPCW, inverse probability of censoring weights; OR, odds ratio; PLHIV, people living with HIV; RAL, raltegravir; T2DM, type 2 diabetes mellitus

[a] Adjusted for baseline age, sex, race, CD4 cell count, HCV, and time-updated BMI, systemic steroid (>14 days). Among ART-experienced/suppressed PLHIV, the models were also adjusted for prior exposure to core agents of interest and AIDS history.